Company Profile
Mesoblast Stock Price, News & Analysis
- Ticker:
- MESO
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- Australia and listed in the U
Stock performance
15.62 USD (+4.41%)
Close
Last updated: August 6, 2026
1.88B USD
Market cap
Why the stock is moving
As of Aug 6, 2026, MESO closed up 4.41% at $15.62. No new same-company headline was identified in the current news window.
Company overview
Business overview
Mesoblast is a regenerative medicine company focused on cell-based therapies for inflammatory and degenerative diseases. Its platform has long centered on developing allogeneic cell therapies with broad medical use.
Geographic Base and Sector Classification
Headquartered in Australia and listed in the U.S. as an ADR, Mesoblast sits in cell therapy and regenerative medicine.
Business Model Characteristics
The company depends on clinical validation, manufacturing execution, and the ability to commercialize cell-based medicine.
Position Within the Biotechnology Landscape
Mesoblast is a long-running regenerative-medicine name whose valuation depends on clinical and commercial milestones.
Future catalysts
Mesoblast's catalysts are Ryoncil commercialization and any broader cell-therapy expansion. The stock will care about whether the commercial base keeps building.
Recent news
- 01
ASX CEO Connect Presentation
Source: Mesoblast
- 02
Quarterly Activities/Appendix 4C Cash Flow Report
Source: Mesoblast
- 03
Patient Recruitment Target Achieved in CLBP Pivotal Trial
Source: Mesoblast
- 04
Appendix 3Y for Gregory George
Source: Mesoblast
- 05
Notification of cessation of securities - MSB
Source: Mesoblast
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Mesoblast (MESO)?
Mesoblast (MESO) most recently closed at 15.62 USD, a +4.41% move versus the previous session.
What is the market cap of Mesoblast (MESO)?
Mesoblast currently has a market capitalization of 1.88B USD on BioPharmSignal.
What does Mesoblast do?
Mesoblast is a regenerative medicine company focused on cell-based therapies for inflammatory and degenerative diseases. Its platform has long centered on developing allogeneic cell therapies with broad medical use.
On which exchange is MESO stock listed?
Mesoblast (MESO) is associated with NASDAQ, Australia and listed in the U, Biopharma.
What is Mesoblast?
Mesoblast's catalysts are Ryoncil commercialization and any broader cell-therapy expansion.
Which conditions is Mesoblast targeting with Mesoblast?
Mesoblast's catalysts are Ryoncil commercialization and any broader cell-therapy expansion.
How does Mesoblast describe recent progress with Mesoblast?
Mesoblast's catalysts are Ryoncil commercialization and any broader cell-therapy expansion.
What is Ryoncil?
Mesoblast's catalysts are Ryoncil commercialization and any broader cell-therapy expansion.